Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.

Biotechnology

Education

Akero

Andrew Cheng

David West

Kitty Yale

Patrick Lamy

Libette Luce

Brittany de Temple

Dominick Villani

Tim Rolph

William White

Jonathan Young

Catriona Yale

Clinical Research and Development

Financial and Accounting Team

Development Team

Leadership Team

Quality Control Team

Teams at Akero

Clinical Research and Development

Financial and Accounting Team

Development Team

Leadership Team

Quality Control Team